^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IMMH-010

i
Other names: IMMH-010, YPD-30, IMMH 010, YPD 30, IMMH010, YPD30
Associations
Trials
Company:
Tianjin Chase Sun Pharma
Drug class:
PD-L1 inhibitor
Related drugs:
Associations
Trials
1year
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=96, Enrolling by invitation, Tianjin Chasesun Pharmaceutical Co., LTD | N=186 --> 96 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
IMMH-010
almost2years
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=186, Enrolling by invitation, Tianjin Chasesun Pharmaceutical Co., LTD | Unknown status --> Enrolling by invitation | Phase classification: P1/2 --> P1 | N=96 --> 186 | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Sep 2021 --> Dec 2023
Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
IMMH-010
over3years
Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug. (PubMed, Pharmaceutics)
We also compared the pharmacokinetic profiles of IMMH-010 in rodents and primates. After oral administration of IMMH-010, the general exposure of active metabolite YPD-29B was slightly lower in primates than in rodents, suggesting that data should be extrapolated cautiously from rodents to humans.
Journal
|
PD-L1 (Programmed death ligand 1) • CES1 (Carboxylesterase 1)
|
IMMH-010
over4years
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=96, Not yet recruiting, Tianjin Chasesun Pharmaceutical Co., LTD
Clinical • New P1/2 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
IMMH-010